Youssef El Douaihy, MD
Gastroenterology · Staten Island, NYNPI 1467707349
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,009 of the $3,297 with a category attached, or 60.9%. Boston Scientific accounts for 83.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $1,598 and has fallen 64.5% since, to $568 in 2025.
Across 33 payments — averaging $99.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Braintree Laboratories, Inc.$159
- Johnson & Johnson$131
- Madrigal Pharmaceuticals$104
- Fujifilm Healthcare Americas Corporation$93
- Ambu Inc.$34
- plus $21 from 1 others
What the payments were for
- Travel & lodging$2,00961%
- Food & beverage$1,28839%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 24 | $2,756 |
| Braintree Laboratories, Inc. | 2 | $159 |
| Johnson & Johnson | 1 | $131 |
| Madrigal Pharmaceuticals | 1 | $104 |
| Fujifilm Healthcare Americas Corporation | 2 | $93 |
| Ambu Inc. | 2 | $34 |
| Gilead | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Apollo ESG NXT System$957
- APOLLO ESG System$154
- Tremfya$131
- REZDIFFRA$104
How this compares
$3,297 in reported general payments places this provider in the 60th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 35 | $562 |
| Colestipol Hcl | 11 | $519 |
| Pantoprazole Sodium | 59 | $461 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Staten Island
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.